Intravenous Milrinone: Are We There yet?

CommentOn

Neurocrit Care. 2025 May 6. doi: 10.1007/s12028-025-02260-x.

COI Statement

Declarations. Conflict of interest: The authors declare that they have no conflict of interest.

References:

• Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, et al. Cerebral arterial spasm—a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308(11):619–24.
• Petruk KC, West M, Mohr G, Weir BK, Benoit BG, Gentili F, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68(4):505–17.
• Fraticelli AT, Cholley BP, Losser MR, Saint Maurice JP, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008;39(3):893–8.
• Lannes M, Teitelbaum J, del Pilar CM, Cardoso M, Angle M. Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol. Neurocrit Care. 2012;16(3):354–62.
• Koyanagi M, Fukuda H, Lo B, Uezato M, Kurosaki Y, Sadamasa N, et al. Effect of intrathecal milrinone injection via lumbar catheter on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2018;128(3):717–22.